M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes Pharmaceutical TechnologyTerremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.M&A / DealsOncologyRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaceutical Technology Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity. M&A / DealsOncologyRead full story Post navigation Previous: Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy studyNext: Most patients “won’t see benefit” with Alzheimer’s drugs Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
